The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

Aura Biosciences, Inc.

The University of New Mexico

Johns Hopkins University

New England Medical Center Hospitals. Inc.

Aleta Biotherapeutics Inc.

Deutsches Krebsforschungszentrum, the German Cancer Research Center

Biosciences, Inc.

John T. Schiller

Douglas R. Lowy

Heather Greenstone

John T Schiller

Douglas R Lowy

Reinhard Kirnbauer

Bryce Chackerian

Elisabet De Los Pinos

Rhonda C Kines

John MacDougall

Alan Thomas Remaley

Marcelo Amar

Richard B S Roden

Diana V Pastrana

Jeff Roberts

Ratish Gambhira

Jeffrey Roberts

Paul David Rennert

Roy R Lobb

Elliot J Androphy

Richard B Roden

John Macdougall

The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.

Virus-like particle conjugates for diagnosis and treatment of tumors

A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

Targeted cancer therapy

Composition comprising PCSK9 peptide conjugated to a Qbeta carrier and methods of using the same

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).

Papillomavirus pseudoviruses for detection and therapy of tumors

PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same

The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide.

Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies

Growing community of inventors

Silver Spring, MD, United States of America

John T Schiller